Princeton Portfolio Strategies Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | $1.56M | Sell |
13,890
-7,387
| -35% | -$832K | 0.3% | 69 |
|
|
2021
Q1 | $2.3M | Hold |
21,277
| – | – | 0.45% | 62 |
|
|
2020
Q4 | $2.28M | Buy |
21,277
+1,350
| +7% | +$130K | 0.45% | 53 |
|
|
2020
Q3 | $1.75M | Hold |
19,927
| – | – | 0.38% | 63 |
|
|
2020
Q2 | $1.96M | Sell |
19,927
-100
| -0.5% | -$8.8K | 0.47% | 56 |
|
|
2020
Q1 | $1.53M | Buy |
20,027
+175
| +0.9% | +$14.9K | 0.44% | 62 |
|
|
2019
Q4 | $1.76M | Buy |
19,852
+2,200
| +12% | +$183K | 0.41% | 65 |
|
|
2019
Q3 | $1.34M | Buy |
17,652
+3,021
| +21% | +$207K | 0.33% | 74 |
|
|
2019
Q2 | $1.06M | Sell |
14,631
-70
| -0.5% | -$5.5K | 0.27% | 84 |
|
|
2019
Q1 | $1.19M | Sell |
14,701
-17,842
| -55% | -$1.46M | 0.32% | 77 |
|
|
2018
Q4 | $3M | Sell |
32,543
-3,835
| -11% | -$337K | 0.93% | 38 |
|
|
2018
Q3 | $3.44M | Sell |
36,378
-48,199
| -57% | -$4.57M | 0.89% | 41 |
|
|
2018
Q2 | $7.84M | Sell |
84,577
-3,385
| -4% | -$331K | 2.27% | 10 |
|
|
2018
Q1 | $8.33M | Sell |
87,962
-20,007
| -19% | -$2.2M | 2.37% | 7 |
|
|
2017
Q4 | $10.4M | Sell |
107,969
-4,534
| -4% | -$427K | 2.85% | 5 |
|
|
2017
Q3 | $10M | Sell |
112,503
-5,233
| -4% | -$398K | 2.71% | 4 |
|
|
2017
Q2 | $8.54M | Sell |
117,736
-6,981
| -6% | -$469K | 2.44% | 5 |
|
|
2017
Q1 | $8.13M | Sell |
124,717
-2,968
| -2% | -$187K | 2.41% | 5 |
|
|
2016
Q4 | $8M | Sell |
127,685
-6,065
| -5% | -$370K | 2.52% | 6 |
|
|
2016
Q3 | $8.44M | Sell |
133,750
-3,120
| -2% | -$202K | 2.65% | 5 |
|
|
2016
Q2 | $8.47M | Buy |
136,870
+3,132
| +2% | +$191K | 2.74% | 3 |
|
|
2016
Q1 | $7.64M | Buy |
133,738
+9,415
| +8% | +$525K | 2.6% | 3 |
|
|
2015
Q4 | $7.37M | Buy |
124,323
+2,205
| +2% | +$127K | 2.61% | 3 |
|
|
2015
Q3 | $6.64M | Sell |
122,118
-120
| -0.1% | -$7.81K | 2.7% | 6 |
|
|
2015
Q2 | $8.21M | Buy |
122,238
+15,195
| +14% | +$992K | 2.89% | 3 |
|
|
2015
Q1 | $6.27M | Buy |
107,043
+92,739
| +648% | +$5.6M | 2.42% | 8 |
|
|
2014
Q4 | $936K | Hold |
14,304
| – | – | 0.37% | 75 |
|
|
2014
Q3 | $826K | Sell |
14,304
-3,136
| -18% | -$174K | 0.35% | 77 |
|
|
2014
Q2 | $984K | Buy |
17,440
+1,900
| +12% | +$99.7K | 0.42% | 74 |
|
|
2014
Q1 | $799K | Sell |
15,540
-4,624
| -23% | -$234K | 0.53% | 67 |
|
|
2013
Q4 | $1.06M | Sell |
20,164
-11,788
| -37% | -$579K | 0.72% | 51 |
|
|
2013
Q3 | $1.43M | Sell |
31,952
-150
| -0.5% | -$6.65K | 1.05% | 33 |
|
|
2013
Q2 | $1.33M | Buy |
+32,102
| New | +$1.4M | 1.09% | 31 |
|
Other funds holding ABBV
Princeton Portfolio Strategies Group's ABBV Position: Q2 2021 in Review
Princeton Portfolio Strategies Group reduced its AbbVie (ABBV) stake by 35% in Q2 2021, selling an estimated $832K and leaving 13,890 shares worth $1.56M. The position accounts for 0.3% of the portfolio, ranked #69.
Princeton Portfolio Strategies Group first reported a position in ABBV in Q2 2013 and has held it in 33 quarters since. The position peaked at $10.4M in Q4 2017. 2,676 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.
- Princeton Portfolio Strategies Group held 13,890 shares of AbbVie worth $1.56M as of Q2 2021.
- Princeton Portfolio Strategies Group sold 7,387 AbbVie shares in Q2 2021, an estimated $832K.
- AbbVie made up 0.3% of Princeton Portfolio Strategies Group's portfolio in Q2 2021, its #69 holding.
- Princeton Portfolio Strategies Group first reported a position in AbbVie in Q2 2013 and has held it in 33 quarters since.
- Princeton Portfolio Strategies Group's AbbVie position peaked at $10.4M in Q4 2017.
- 2,676 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.
Based on Princeton Portfolio Strategies Group's 13F filing for Q2 2021, filed 2 Aug 2021.